PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 106 filers reported holding PMV PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,267,456 | +102.5% | 5,255,286 | +106.5% | 3.52% | -14.0% |
| Q2 2023 | $15,933,215 | +42.9% | 2,545,242 | +8.9% | 4.09% | -58.1% |
| Q1 2023 | $11,147,056 | -45.2% | 2,336,909 | 0.0% | 9.78% | -48.6% |
| Q4 2022 | $20,331,108 | -26.9% | 2,336,909 | 0.0% | 19.02% | -26.3% |
| Q3 2022 | $27,809,000 | -16.5% | 2,336,909 | 0.0% | 25.82% | -8.8% |
| Q2 2022 | $33,301,000 | -31.6% | 2,336,909 | 0.0% | 28.32% | +0.2% |
| Q1 2022 | $48,654,000 | -9.9% | 2,336,909 | 0.0% | 28.27% | -7.9% |
| Q4 2021 | $53,983,000 | -34.6% | 2,336,909 | -15.6% | 30.69% | -23.5% |
| Q3 2021 | $82,540,000 | -38.2% | 2,769,813 | -29.1% | 40.12% | -7.4% |
| Q2 2021 | $133,520,000 | -2.9% | 3,908,677 | -6.5% | 43.34% | -5.8% |
| Q1 2021 | $137,461,000 | -46.5% | 4,179,416 | 0.0% | 45.99% | -15.5% |
| Q4 2020 | $257,076,000 | – | 4,179,416 | – | 54.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |